Active	Status	Sponsor type	Region	Phase	Filter
6 Active 0 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Poissant, Sarah
LX1001-01, NCT03634007: Gene Therapy for APOE4 Homozygote of Alzheimer's Disease	Active, not recruiting	1/2	15	US	LX1001, AAVrh.10hAPOE2	Lexeo Therapeutics, Alzheimer's Drug Discovery Foundation, Weill Medical College of Cornell University	Alzheimer Disease, Early Onset Alzheimer Disease	11/24	11/24
PROPEL, NCT04127578: Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation	Recruiting	1/2	20	US, RoW	LY3884961, Methylprednisolone, Sirolimus	Prevail Therapeutics, Eli Lilly and Company	Parkinson Disease	06/29	06/29
FTD-GRN, NCT04408625: Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations	Recruiting	1/2	30	Europe, US, RoW	LY3884963, Methylprednisolone, Optional Sirolimus, Optional Prednisone	Prevail Therapeutics, Eli Lilly and Company	Frontotemporal Dementia	08/29	08/29
Cedano, Gina
APOLLOE4-LTE, NCT06304883: Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects	Enrolling by invitation	3	285	Europe, Canada, US	Experimental: ALZ-801	Alzheon Inc.	Early Alzheimer's Disease	12/25	01/26
NCT05686044: A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD	Completed	2/3	320	US	Buntanetap/Posiphen, Posiphen Tartrate, Placebo	Annovis Bio Inc.	Alzheimer Disease	02/24	02/24
FTD-GRN, NCT04408625: Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations	Recruiting	1/2	30	Europe, US, RoW	LY3884963, Methylprednisolone, Optional Sirolimus, Optional Prednisone	Prevail Therapeutics, Eli Lilly and Company	Frontotemporal Dementia	08/29	08/29